Literature DB >> 9386808

Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy.

H R Brodt1, B S Kamps, P Gute, B Knupp, S Staszewski, E B Helm.   

Abstract

OBJECTIVE: To determine the incidence of AIDS-defining opportunistic infections and malignancies over a 5-year period from 1992 to 1996. STUDY POPULATION: Subcohort of 1003 homosexual men with HIV infection and CD4 count less than 200 x 10(6) cells/l from the Frankfurt AIDS Cohort Study.
METHODS: Data including the earliest date that a CD4 T-lymphocyte count < 200 x 10(6)/l was reached and the dates of AIDS-defining events were compiled from medical records. Incidence analyses for AIDS-defining events and death during the subsequent 5 years (1992-1996) were performed using rates per 100 person-years of exposure.
RESULTS: During the observation period, the number of patients per year with CD4 T-lymphocyte counts < 200 x 10(6)/l varied between 402 and 511. In 1992, 56.7% of patients experienced at least one AIDS-defining illness, and 20.7% in 1996. The annual number of AIDS-defining events per 100 patient-years of observation declined from 143.5 in 1992 to 38.3 in 1996, and the number of AIDS-related deaths fell from 25.7 to 12.9. Analysis of the number of events confirmed this trend for malignancies and single opportunistic infections, with the exception of mycobacterial diseases.
CONCLUSIONS: The incidence of AIDS-defining events in patients with advanced HIV infection at Frankfurt University Hospital has declined by more than 70% from 1992 to 1996.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9386808     DOI: 10.1097/00002030-199714000-00010

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  74 in total

1.  Design of dimerization inhibitors of HIV-1 aspartic proteinase: a computer-based combinatorial approach.

Authors:  A Caflisch; H J Schramm; M Karplus
Journal:  J Comput Aided Mol Des       Date:  2000-02       Impact factor: 3.686

Review 2.  HTLV-1 and HIV infections of the central nervous system in tropical areas.

Authors:  P Cabre; D Smadja; A Cabié; C R Newton
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-05       Impact factor: 10.154

3.  Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART).

Authors:  M Maschke; O Kastrup; S Esser; B Ross; U Hengge; A Hufnagel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-09       Impact factor: 10.154

Review 4.  Prophylaxis of Pneumocystis carinii pneumonia: too much of a good thing?

Authors:  R F Miller
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

Review 5.  Virus receptors in the human central nervous system.

Authors:  B Schweighardt; W J Atwood
Journal:  J Neurovirol       Date:  2001-06       Impact factor: 2.643

Review 6.  Human immunodeficiency virus-associated dementia: an evolving disease.

Authors:  Justin C McArthur; Norman Haughey; Suzanne Gartner; Kathy Conant; Carlos Pardo; Avi Nath; Ned Sacktor
Journal:  J Neurovirol       Date:  2003-04       Impact factor: 2.643

Review 7.  Impact of antiretroviral therapy on the incidence of Kaposi's sarcoma in resource-rich and resource-limited settings.

Authors:  Aggrey S Semeere; Naftali Busakhala; Jeffrey N Martin
Journal:  Curr Opin Oncol       Date:  2012-09       Impact factor: 3.645

8.  Retention in Care of HIV-Positive Postpartum Females in Kumasi, Ghana.

Authors:  Rebecca Reece; Betty Norman; Awewura Kwara; Timothy Flanigan; Aadia Rana
Journal:  J Int Assoc Provid AIDS Care       Date:  2015-08-28

Review 9.  Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.

Authors:  Louis de Repentigny; Daniel Lewandowski; Paul Jolicoeur
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

10.  The effect of highly active antiretroviral therapy on outcome of central nervous system herpesviruses infection in Cuban human immunodeficiency virus-infected individuals.

Authors:  Pedro Ariel Martínez; René Díaz; Daniel González; Lisset Oropesa; Ruby González; Lissette Pérez; Jenniffer Viera; Vivian Kourí
Journal:  J Neurovirol       Date:  2007-10       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.